Longevity announces continued Nasdaq listing to complete 20/20 BioLabs deal

Written by Emily J. Thompson, Senior Investment Analyst

XAGE%

Updated: May 21 2025

0mins

Nasdaq Listing Approval: Longevity Health has received approval from the Nasdaq Hearings Panel to continue its listing, contingent upon meeting initial listing rules after merging with 20/20 BioLabs by September 2.
Merger and Stock Split: The company plans to merge with 20/20 and implement a 1-for-30 reverse stock split as part of its strategy to comply with Nasdaq's requirements, having filed the necessary registration statement on May 8 and executed the stock split on May 12.

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.

Longevity announces continued Nasdaq listing to complete 20/20 BioLabs deal

About the author

Top News

Oil Firms Cautious on Venezuela Investment Push

GM Reports $7.1 Billion Charge Amid EV Shift

Stock Market Wraps 2025 with Double-Digit Gains

Novo Nordisk's Weight-Loss Pill Approval: Key Impacts

Related Articles

Amazon's AI Growth Fuels Stock Rise, Nasdaq Predicted to Soar by 2026

Peter Thiel Sells Nvidia, Invests in Apple and Microsoft

Sigh Up to Get Intellectia Insights

How did the company's recent strategic decisions impact its latest financial performance?

Can you explain the factors behind the recent changes in the company's stock price?

What are the expected impacts of current market trends on the company's future growth?

Based on the latest earnings report, what are the company's forecasted revenues for the next quarter?

How does the company's performance compare to its main competitors in the same sector?

People Also Watch